Robert Motzer, MD, unpacks LITESPARK-011 results of belzutifan plus lenvatinib in advanced RCC
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Results from the LITESPARK-011 study of belzutifan plus lenvatinib in advanced renal cell carcinoma (RCC) have been discussed by Robert Motzer, MD. The study's findings are being reviewed in relation to the treatment of advanced RCC. Details of the results are being presented, but the outcomes are not specified in the available information.